Hub : Traits :

Asthma (self-reported)

710 significantly associated models · 166 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7715776	11137778	5	2	3.1e-09	4.1e-09	9.8e-02	92	KIF1B RERE
2	1	151055670	152712747	3	6	4.6e-12	1.8e-13	1.0e+00	100	LINGO4 S100A11 TDRKH
3	1	166702558	168182443	1	1	3.0e-12	2.0e-12	1.0e+00	100	CD247
4	1	172311679	173713130	2	1	3.6e-08	4.4e-08	3.6e-09	-16	TNFSF4
5	1	202888496	203393566	1	1	5.9e-09	1.1e-08	1.0e+00	100	MYBPH
6	2	99922967	100994580	1	1	1.9e-07	4.8e-08	3.9e-02	86	AFF3
7	2	101994731	104027106	6	8	9.8e-63	9.1e-51	NaN	NaN	IL18R1 IL1R1 IL1RL1 SLC9A2
8	2	241941773	243048760	8	3	1.4e-24	4.6e-25	2.9e-01	99	D2HGDH ING5
9	3	127097277	128533990	2	1	9.6e-09	6.9e-08	3.8e-01	97	EEFSEC
10	4	38097478	39643536	4	1	4.1e-14	3.6e-15	4.0e-03	87	TLR1
11	4	122377715	123976639	1	1	3.6e-17	4.3e-14	7.6e-03	88	KIAA1109
12	5	35608310	36124514	1	1	6.1e-08	3.9e-08	1.0e+00	100	IL7R
13	5	109381583	111527482	5	7	4.0e-21	8.1e-40	NaN	NaN	SLC25A46 TMEM232 TSLP
14	5	130588008	132900729	16	7	3.8e-23	2.7e-25	NaN	NaN	AC034220.3 KIF3A P4HA2-AS1 SLC22A5
15	5	140789933	142230251	1	1	1.1e-09	2.9e-09	1.6e-02	84	NDFIP1
16	5	156131251	157697754	1	1	1.2e-09	1.3e-09	9.4e-04	70	ADAM19
17	6	25266147	26682323	1	1	1.6e-07	8.0e-10	1.0e-06	37	TRIM38
18	6	34528785	35987507	3	1	2.1e-08	1.1e-09	7.4e-03	81	ZNF76
19	6	63986735	64534000	1	1	3.5e-08	1.7e-08	8.5e-02	91	PTP4A1
20	6	89941356	91704536	1	2	7.0e-18	3.7e-27	3.7e-07	78	BACH2
21	6	134905567	136516257	2	2	2.0e-13	2.5e-09	7.1e-01	100	AHI1
22	7	27623776	28468319	1	1	5.8e-08	1.2e-13	3.4e-07	53	JAZF1
23	9	4934896	7345375	5	3	5.5e-28	1.5e-56	1.4e-22	62	GLDC KIAA1432 RANBP6
24	10	74879374	76266883	1	1	1.4e-07	4.0e-05	2.9e-01	93	RP11-574K11.5
25	10	93657148	95110026	1	1	1.3e-07	1.7e-08	9.8e-03	79	KIF11
26	11	60839578	62346131	6	1	3.8e-11	3.3e-11	3.9e-02	90	FADS1
27	11	64845438	66333072	4	1	3.6e-09	2.5e-10	1.7e-05	54	EFEMP2
28	11	75678647	77069746	1	1	2.6e-25	2.4e-44	7.9e-22	53	LRRC32
29	11	110776537	112287801	1	1	7.6e-09	1.1e-09	1.0e+00	100	SIK2
30	12	5809999	6956462	1	1	2.0e-07	1.6e-07	1.1e-01	91	RP1-102E24.8
31	12	47407397	48825686	1	1	6.5e-08	6.5e-06	1.5e-02	71	RP1-197B17.3
32	12	55601472	58677299	12	4	6.1e-17	1.6e-23	1.4e-02	94	GPR182 KIF5A RPS26 STAT6
33	12	120502726	122037099	1	1	1.3e-08	6.7e-08	5.1e-02	87	SPPL3
34	13	99047988	100728229	3	3	2.7e-13	6.1e-17	3.9e-02	94	UBAC2
35	14	92733536	93401178	1	1	1.9e-09	1.0e-05	8.4e-03	64	RIN3
36	15	66662107	68789191	4	4	5.2e-32	8.5e-37	6.5e-04	93	IQCH SMAD3
37	16	10325245	12010444	5	2	4.9e-19	2.3e-26	8.8e-07	79	CLEC16A RP11-396B14.2
38	16	26518263	28065536	5	2	3.3e-13	2.0e-12	9.0e-04	78	CTD-3203P2.1 IL4R
39	17	36710513	39068227	24	9	7.6e-52	1.4e-50	1.0e+00	100	CASC3 GSDMA KRT222 MED24 ORMDL3
40	17	39993748	41538783	4	1	6.4e-08	1.1e-07	4.4e-05	41	RP11-400F19.8
41	17	42624404	43570226	1	1	3.4e-09	3.6e-09	8.8e-03	80	CTD-2020K17.3
42	17	46581184	48139500	2	1	2.4e-14	5.9e-16	3.0e-03	86	ZNF652
43	18	51553172	52058680	1	1	1.4e-07	3.1e-06	4.1e-01	97	POLI
44	19	15771809	17268784	1	1	1.3e-07	7.8e-06	3.6e-03	58	EPS15L1
45	19	45585167	46994833	3	1	7.6e-09	1.0e-09	4.0e-02	89	DMWD
46	19	52049899	52574723	1	1	3.0e-07	1.5e-05	3.1e-04	31	FPR3
47	20	62024275	62614338	2	1	4.5e-08	2.9e-06	8.5e-01	100	STMN3
48	22	41071659	42685537	7	1	3.1e-08	8.0e-08	4.9e-01	98	PHF5A

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Asthma	30.93	72	67	148.9	1.00	7.3e-152	AC034220.3 ADAM19 AFF3 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3203P2.1 D2HGDH DMWD EEFSEC EFEMP2 EPS15L1 FADS1 FPR3 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 MYBPH NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI PTP4A1 RANBP6 RERE RIN3 RP1-102E24.8 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RP1-197B17.3 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TMEM232 TNFSF4 TRIM38 TSLP UBAC2 ZNF652 ZNF76
Allergy	30.79	64	53	117.8	-0.97	5.2e-53	AC034220.3 AFF3 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3203P2.1 D2HGDH EEFSEC EFEMP2 EPS15L1 FADS1 FPR3 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TMEM232 TNFSF4 TSLP UBAC2 ZNF652
Respiratory disease	29.78	66	59	131.1	1.00	2.9e-95	AC034220.3 ADAM19 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-2020K17.3 CTD-3203P2.1 D2HGDH DMWD EEFSEC EFEMP2 FADS1 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KIF5A KRT222 LINGO4 LRRC32 MED24 MYBPH NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI PTP4A1 RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RP1-197B17.3 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TNFSF4 TSLP UBAC2 ZNF652 ZNF76
Blood Eosinophil Count	27.60	52	46	102.2	0.91	5.6e-28	AC034220.3 AHI1 BACH2 CASC3 CD247 CLEC16A CTD-3203P2.1 D2HGDH DMWD EFEMP2 FADS1 FPR3 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH KIAA1109 KIAA1432 KIF11 KIF1B KIF3A KRT222 LRRC32 MED24 NDFIP1 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP1-102E24.8 RP11-396B14.2 RPS26 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 TMEM232 TSLP UBAC2 ZNF652 ZNF76
Allergy or Eczema	26.82	54	45	100.0	0.93	1.6e-32	AHI1 BACH2 CASC3 CD247 CLEC16A CTD-3203P2.1 D2HGDH EFEMP2 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R ING5 IQCH JAZF1 KIAA1109 KIAA1432 KIF3A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RP11-574K11.5 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TDRKH TLR1 TMEM232 TNFSF4 TSLP UBAC2 ZNF652
Hayfever, allergic rhinitis or eczema	23.91	49	41	91.1	0.94	3.4e-31	AHI1 BACH2 CD247 CLEC16A CTD-3203P2.1 D2HGDH EFEMP2 GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 IL4R IL7R JAZF1 KIAA1109 KIAA1432 KIF3A KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A POLI RANBP6 RERE RIN3 RP11-396B14.2 RP11-400F19.8 RPS26 S100A11 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 SPPL3 STAT6 STMN3 TLR1 TMEM232 TNFSF4 TSLP UBAC2 ZNF652
Medication: Ventolin 100micrograms inhaler	13.20	29	8	17.8	0.99	9.8e-31	AFF3 AHI1 BACH2 CD247 CLEC16A CTD-2020K17.3 D2HGDH GLDC GPR182 GSDMA IL18R1 IL1RL1 ING5 IQCH KIAA1109 KIAA1432 LINGO4 LRRC32 NDFIP1 ORMDL3 RANBP6 RPS26 SLC22A5 SLC9A2 SMAD3 STAT6 TLR1 TSLP ZNF652
Blood White Count	13.18	27	18	40.0	0.62	4.6e-05	AC034220.3 AHI1 BACH2 CASC3 CLEC16A EFEMP2 EPS15L1 FADS1 GSDMA IL1RL1 KIF1B KIF3A MED24 NDFIP1 ORMDL3 P4HA2-AS1 POLI RERE RIN3 RP1-102E24.8 RP11-396B14.2 RP11-400F19.8 SLC22A5 SPPL3 STMN3 ZNF652 ZNF76
Hayfever/allergic rhinitis (self-reported)	12.41	25	14	31.1	0.96	1.4e-20	BACH2 CD247 CLEC16A D2HGDH GLDC GPR182 IL18R1 IL1RL1 IL7R KIAA1109 KIAA1432 KRT222 LRRC32 ORMDL3 RANBP6 RP11-396B14.2 RPS26 SLC25A46 SLC9A2 SMAD3 STAT6 TLR1 TMEM232 TNFSF4 TSLP
Wheeze or whistling in the chest in last year	12.05	34	18	40.0	0.99	4.5e-37	ADAM19 AFF3 BACH2 CASC3 CD247 CLEC16A D2HGDH GLDC GPR182 GSDMA IL18R1 IL1R1 IL1RL1 ING5 JAZF1 KIAA1109 KIAA1432 LINGO4 LRRC32 MED24 ORMDL3 RERE RIN3 RP11-396B14.2 RP11-574K11.5 SIK2 SLC22A5 SLC25A46 SLC9A2 SMAD3 STMN3 TSLP UBAC2 ZNF652
Medication: Seretide 50 evohaler	6.65	8	1	2.2	0.98	1.1e-10	BACH2 D2HGDH IL18R1 IL1RL1 P4HA2-AS1 SLC22A5 SMAD3 ZNF652
Crohns Disease (2017)	5.72	18	9	20.0	-0.13	5.7e-01	AC034220.3 BACH2 CASC3 FADS1 GSDMA KIAA1109 KIF11 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RP11-574K11.5 SLC22A5 SMAD3 STMN3 TNFSF4
Irritable Bowel Disease (IBD)	5.37	17	13	28.9	-0.12	5.8e-01	AC034220.3 BACH2 CASC3 GSDMA KIAA1109 KIF11 KRT222 LINGO4 LRRC32 MED24 NDFIP1 ORMDL3 P4HA2-AS1 RP11-574K11.5 SLC22A5 SMAD3 STMN3
Lung FEV1/FVC ratio	4.78	23	15	33.3	-0.79	6.4e-08	ADAM19 BACH2 D2HGDH DMWD EEFSEC GLDC IL18R1 IL1RL1 IL7R KIAA1432 MED24 MYBPH ORMDL3 P4HA2-AS1 RP11-396B14.2 RP11-574K11.5 RPS26 SLC22A5 SLC9A2 SMAD3 STAT6 ZNF652 ZNF76
Number of self-reported non-cancer illnesses	4.76	12	3	6.7	0.94	3.2e-07	D2HGDH EEFSEC IL1RL1 IQCH LINGO4 LRRC32 ORMDL3 P4HA2-AS1 PHF5A RP11-396B14.2 SLC22A5 ZNF652
Crohns Disease (2012)	4.58	10	6	13.3	-0.24	4.3e-01	AC034220.3 FADS1 GSDMA LRRC32 NDFIP1 ORMDL3 P4HA2-AS1 SLC22A5 SMAD3 STMN3
Taking other prescription medications	4.24	7	2	4.4	0.92	3.7e-04	AHI1 D2HGDH GSDMA IL1RL1 IQCH ORMDL3 ZNF652
Ulcerative Colitis (UC)	3.15	9	5	11.1	-0.09	7.8e-01	CASC3 GSDMA KIAA1109 KRT222 LINGO4 LRRC32 MED24 ORMDL3 SMAD3
Hypothyroidism (self reported)	3.15	12	5	11.1	-0.09	7.7e-01	AHI1 BACH2 CD247 FADS1 IL7R KIAA1109 PHF5A RERE RPS26 SPPL3 TLR1 UBAC2
Hypothyroidism/myxoedema (self-reported)	2.93	6	3	6.7	-0.14	7.7e-01	AHI1 BACH2 CD247 IL7R KIAA1109 RPS26
Medication: Levothyroxine sodium	2.81	5	2	4.4	0.14	7.9e-01	AHI1 BACH2 FADS1 IL7R RPS26
Ulcerative Colitis	2.65	4	2	4.4	-0.64	3.6e-01	GSDMA KIAA1109 MED24 ORMDL3
Number of treatments/medications taken	2.51	4	1	2.2	0.97	2.6e-02	CLEC16A P4HA2-AS1 SLC9A2 ZNF652
Forced expiratory volume in 1-second (FEV1), Best measure	2.26	10	6	13.3	-0.91	4.7e-05	ADAM19 AHI1 EEFSEC LINGO4 P4HA2-AS1 RP11-574K11.5 RPS26 SLC22A5 TRIM38 ZNF76
Primary Biliary Cirrhosis	2.25	3	2	4.4	0.00	1.0e+00	GSDMA IL7R ORMDL3
Blood Platelet Count	2.23	19	18	40.0	0.41	6.2e-02	AC034220.3 DMWD EEFSEC FADS1 ING5 KIF1B KIF3A KIF5A MED24 NDFIP1 ORMDL3 P4HA2-AS1 PHF5A RP1-102E24.8 RP1-197B17.3 SIK2 SLC22A5 SPPL3 STMN3
HDL Cholesterol	2.21	5	2	4.4	-0.17	7.8e-01	FADS1 FPR3 GSDMA KIF5A ORMDL3
Forced expiratory volume in 1-second (FEV1)	2.19	11	6	13.3	-0.92	9.3e-06	ADAM19 AHI1 EEFSEC LINGO4 P4HA2-AS1 RP11-574K11.5 RPS26 SLC22A5 STMN3 TRIM38 ZNF76
Long-standing illness, disability or infirmity	2.19	2	0	0.0	0.00	1.0e+00	IQCH ZNF652
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.15	6	2	4.4	-0.92	9.8e-03	ADAM19 ORMDL3 RPS26 STMN3 TRIM38 ZNF76
Chest pain or discomfort	2.13	1	0	0.0	0.00	1.0e+00	IL1RL1
Hand grip strength (right)	1.96	6	4	8.9	-0.97	9.1e-06	AC034220.3 KIF1B P4HA2-AS1 SLC22A5 STAT6 ZNF76
Headache pain in last month	1.95	3	1	2.2	0.00	1.0e+00	DMWD RPS26 STAT6
Lung FVC	1.88	14	10	22.2	-0.19	4.8e-01	AC034220.3 AHI1 CLEC16A IQCH KIF1B LINGO4 P4HA2-AS1 RIN3 RP11-574K11.5 RPS26 SLC22A5 SPPL3 STMN3 ZNF76
Hand grip strength (left)	1.87	5	4	8.9	-0.99	3.2e-05	AC034220.3 KIF1B P4HA2-AS1 SLC22A5 ZNF76
Standing height	1.86	13	9	20.0	-0.76	7.2e-04	AC034220.3 AFF3 DMWD FADS1 IQCH P4HA2-AS1 PHF5A RERE SLC22A5 SPPL3 STAT6 ZNF652 ZNF76
Vascular/heart problems diagnosed by doctor	1.86	9	5	11.1	-0.64	3.5e-02	AC034220.3 EEFSEC IQCH P4HA2-AS1 RERE SIK2 SLC22A5 SMAD3 ZNF652
Breast Cancer	1.82	7	3	6.7	0.65	7.9e-02	EFEMP2 KIF1B P4HA2-AS1 RP11-400F19.8 SIK2 SLC22A5 TLR1
Height	1.82	21	13	28.9	-0.56	4.8e-03	AC034220.3 AFF3 AHI1 CASC3 DMWD FADS1 IL1R1 IL1RL1 IQCH KIF11 KIF1B NDFIP1 P4HA2-AS1 PHF5A RERE SLC22A5 SMAD3 SPPL3 STAT6 ZNF652 ZNF76
Chronic bronchitis/emphysema (father)	1.82	1	0	0.0	0.00	1.0e+00	IQCH
Prostate Cancer	1.79	2	1	2.2	0.00	1.0e+00	EEFSEC STMN3
Triglycerides	1.78	2	2	4.4	0.00	1.0e+00	FADS1 KIF5A
Forced expiratory volume in 1-second (FEV1), predicted	1.73	4	4	8.9	-0.97	1.6e-03	AC034220.3 P4HA2-AS1 SLC22A5 ZNF76
Rheumatoid Arthritis	1.72	1	0	0.0	0.00	1.0e+00	ORMDL3
Illnesses of father: Heart disease	1.72	2	0	0.0	0.00	1.0e+00	SIK2 SMAD3
Medication: Blood pressure	1.71	4	0	0.0	0.73	1.6e-01	AC034220.3 P4HA2-AS1 SIK2 SLC22A5
Migraine (self-reported)	1.70	1	1	2.2	0.00	1.0e+00	STAT6
Hypertension (Self-reported)	1.70	9	4	8.9	0.51	1.1e-01	AC034220.3 EEFSEC P4HA2-AS1 POLI RERE RPS26 SIK2 SLC22A5 ZNF652
High blood pressure	1.68	10	4	8.9	0.56	6.1e-02	AC034220.3 EEFSEC IQCH P4HA2-AS1 POLI RERE RPS26 SIK2 SLC22A5 ZNF652
Father's age at death	1.66	1	0	0.0	0.00	1.0e+00	SLC22A5
Mouth/teeth dental problems: Mouth ulcers	1.66	1	0	0.0	0.00	1.0e+00	ORMDL3
Lupus	1.63	1	0	0.0	0.00	1.0e+00	ZNF76
Medication: Bendroflumethiazide	1.63	3	0	0.0	0.99	1.4e-02	AC034220.3 P4HA2-AS1 SLC22A5
Type 2 Diabetes (T2D) (2012)	1.62	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Hair/balding pattern: Pattern 4	1.61	5	0	0.0	0.39	5.2e-01	CTD-2020K17.3 FADS1 IQCH KIF1B S100A11
Comparative height size at age 10	1.61	8	6	13.3	-0.69	2.6e-02	AC034220.3 DMWD IQCH KIF11 P4HA2-AS1 SLC22A5 SMAD3 ZNF76
Gout (self-reported)	1.57	1	1	2.2	0.00	1.0e+00	KIF5A
Birth weight of first child	1.54	2	1	2.2	0.00	1.0e+00	RPS26 ZNF76
Medication: Blood pressure	1.54	2	2	4.4	0.00	1.0e+00	SIK2 ZNF652
Medication for pain relief, constipation, heartburn	1.53	1	1	2.2	0.00	1.0e+00	STAT6
Diabetes diagnosed by doctor	1.51	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Peak expiratory flow (PEF)	1.47	3	2	4.4	0.00	1.0e+00	ADAM19 SLC22A5 ZNF76
Vitamin and mineral supplements	1.46	1	1	2.2	0.00	1.0e+00	STAT6
Trunk predicted mass	1.44	7	7	15.6	-0.98	5.6e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Trunk fat-free mass	1.43	7	7	15.6	-0.98	5.8e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Number of operations (self-reported)	1.43	1	0	0.0	0.00	1.0e+00	IQCH
Cardiovascular Disease	1.42	7	2	4.4	0.51	2.4e-01	EEFSEC KRT222 RERE SIK2 SLC22A5 ZNF652 ZNF76
Impedance of arm (right)	1.42	11	8	17.8	0.63	2.9e-02	EEFSEC GSDMA KIF1B LRRC32 MED24 NDFIP1 PHF5A RIN3 RPS26 SMAD3 ZNF652
Medication: Paracetamol	1.42	1	1	2.2	0.00	1.0e+00	STAT6
Bipolar Disorder or Schizophrenia	1.41	3	0	0.0	0.00	1.0e+00	MED24 STAT6 TRIM38
Forced vital capacity (FVC)	1.41	7	3	6.7	-0.82	7.0e-03	AHI1 IQCH LINGO4 RP11-574K11.5 STMN3 TRIM38 ZNF76
Medication: Simvastatin	1.41	1	0	0.0	0.00	1.0e+00	DMWD
Birth weight	1.41	3	1	2.2	0.00	1.0e+00	KIF11 SIK2 ZNF76
Myopia	1.41	1	0	0.0	0.00	1.0e+00	STAT6
Medication: Allopurinol	1.40	1	1	2.2	0.00	1.0e+00	KIF5A
Whole body water mass	1.40	7	6	13.3	-0.97	8.7e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Medication for cholesterol, blood pressure or diabetes	1.39	2	1	2.2	0.00	1.0e+00	SIK2 ZNF652
Shortness of breath walking on level ground	1.39	1	0	0.0	0.00	1.0e+00	LRRC32
Medication: Aspirin	1.39	1	0	0.0	0.00	1.0e+00	SIK2
Diastolic blood pressure, automated reading	1.39	5	1	2.2	0.98	3.6e-03	AC034220.3 P4HA2-AS1 RERE ZNF652 ZNF76
LDL Cholesterol	1.38	1	1	2.2	0.00	1.0e+00	FADS1
Forced vital capacity (FVC), Best measure	1.38	8	2	4.4	-0.85	1.8e-03	AHI1 IQCH LINGO4 RP11-574K11.5 RPS26 STMN3 TRIM38 ZNF76
Whole body fat-free mass	1.38	7	6	13.3	-0.97	8.1e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 STAT6 ZNF76
Alcohol drinker status: Never	1.38	1	0	0.0	0.00	1.0e+00	SLC9A2
Heart attack/myocardial infarction (self-reported)	1.38	1	0	0.0	0.00	1.0e+00	ZNF652
Medication: Ibuprofen	1.37	1	1	2.2	0.00	1.0e+00	STAT6
Bipolar Disorder (2018)	1.36	1	0	0.0	0.00	1.0e+00	MED24
Medication: Metformin	1.36	1	0	0.0	0.00	1.0e+00	KIF11
Medication: Ibuprofen (e.g. Nurofen)	1.36	1	1	2.2	0.00	1.0e+00	STAT6
Impedance of arm (left)	1.36	11	5	11.1	0.60	3.9e-02	CTD-2020K17.3 EEFSEC GSDMA KIF1B LRRC32 MED24 PHF5A RIN3 RPS26 SMAD3 ZNF652
Arm predicted mass (left)	1.36	6	6	13.3	-0.99	7.1e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Diabetes (self-reported)	1.35	3	1	2.2	0.00	1.0e+00	JAZF1 KIF11 RP11-400F19.8
Leg fat-free mass (left)	1.34	8	4	8.9	-0.88	7.6e-04	AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 TRIM38 ZNF76
Leg predicted mass (left)	1.34	7	4	8.9	-0.98	4.6e-06	AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Arm predicted mass (right)	1.34	7	6	13.3	-0.98	3.9e-06	AC034220.3 MED24 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Medication: Aspirin	1.34	1	0	0.0	0.00	1.0e+00	SIK2
Arm fat-free mass (right)	1.33	7	6	13.3	-0.98	3.2e-06	AC034220.3 MED24 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Heart attack	1.32	2	0	0.0	0.00	1.0e+00	KIF5A ZNF652
Illnesses of father: None of the above (group 1)	1.32	1	0	0.0	0.00	1.0e+00	SMAD3
Leg predicted mass (right)	1.32	7	4	8.9	-0.98	3.9e-06	AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Fractured/broken bones in last 5 years	1.32	1	0	0.0	0.00	1.0e+00	IQCH
Type 2 Diabetes (T2D) (2018)	1.31	2	1	2.2	0.00	1.0e+00	JAZF1 KIF11
Current tobacco smoking	1.31	1	1	2.2	0.00	1.0e+00	PHF5A
Age when periods started (menarche)	1.31	4	0	0.0	0.46	5.4e-01	EEFSEC IQCH RPS26 SPPL3
Leg fat-free mass (right)	1.31	7	4	8.9	-0.98	3.7e-06	AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Basal metabolic rate	1.31	7	5	11.1	-0.98	1.8e-06	AC034220.3 P4HA2-AS1 RIN3 RP11-400F19.8 RPS26 SLC22A5 ZNF76
Arm fat-free mass (left)	1.31	6	6	13.3	-0.99	5.8e-06	AC034220.3 P4HA2-AS1 RIN3 RPS26 SLC22A5 ZNF76
Fasting Glucose	1.30	1	1	2.2	0.00	1.0e+00	FADS1
Multivitamins +/- minerals	1.30	1	0	0.0	0.00	1.0e+00	STAT6
Leg fat percentage (left)	1.30	8	1	2.2	0.64	8.5e-02	IQCH KRT222 RERE RP11-400F19.8 SMAD3 STMN3 TRIM38 ZNF76
Smoking Status	1.29	4	2	4.4	0.22	7.8e-01	IQCH PHF5A RPS26 ZNF652
Average weekly red wine intake	1.29	1	0	0.0	0.00	1.0e+00	RP11-400F19.8
Leg fat percentage (right)	1.27	7	1	2.2	0.63	1.3e-01	IQCH KRT222 RERE RP11-400F19.8 SMAD3 STMN3 TRIM38
Angina	1.26	2	1	2.2	0.00	1.0e+00	AFF3 ZNF652
Had major operations	1.24	1	0	0.0	0.00	1.0e+00	ZNF652
Mineral and other dietary supplements	1.24	1	0	0.0	0.00	1.0e+00	STAT6
Sitting height	1.23	7	6	13.3	-0.85	2.0e-03	AC034220.3 DMWD P4HA2-AS1 SLC22A5 STAT6 ZNF652 ZNF76
Number of live births	1.23	1	1	2.2	0.00	1.0e+00	FADS1
Smoking status: Current	1.22	1	1	2.2	0.00	1.0e+00	PHF5A
Impedance of whole body	1.22	9	5	11.1	0.33	3.8e-01	EEFSEC KIF1B LRRC32 MED24 PHF5A RIN3 RP11-400F19.8 RPS26 ZNF652
Pulse rate, automated reading	1.21	3	1	2.2	0.00	1.0e+00	FADS1 RPS26 SIK2
Schizophrenia (2018)	1.20	2	1	2.2	0.00	1.0e+00	STAT6 TRIM38
Angina (self-reported)	1.20	1	0	0.0	0.00	1.0e+00	ZNF652
Pain experienced in last month	1.20	2	0	0.0	0.00	1.0e+00	RPS26 STAT6
Past tobacco smoking	1.19	2	1	2.2	0.00	1.0e+00	GLDC IQCH
Smoking status: Previous	1.19	1	0	0.0	0.00	1.0e+00	IQCH
Cholesterol lowering medication	1.19	1	0	0.0	0.00	1.0e+00	DMWD
Waist Hip Ratio (WHR)	1.18	7	0	0.0	0.02	9.6e-01	AFF3 DMWD IQCH MED24 RP11-396B14.2 RP11-400F19.8 SIK2
Tense / 'highly strung'	1.18	2	0	0.0	0.00	1.0e+00	PHF5A RERE
Ever had bowel cancer screening	1.18	1	0	0.0	0.00	1.0e+00	SIK2
Average weekly champagne plus white wine intake	1.18	1	0	0.0	0.00	1.0e+00	FADS1
Maternal smoking around birth	1.17	1	0	0.0	0.00	1.0e+00	PHF5A
Fluid intelligence score	1.17	2	0	0.0	0.00	1.0e+00	AFF3 RPS26
Comparative body size at age 10	1.17	3	1	2.2	0.00	1.0e+00	IQCH SMAD3 ZNF652
Age at first live birth	1.16	1	0	0.0	0.00	1.0e+00	RPS26
Medication: Paracetamol	1.16	1	1	2.2	0.00	1.0e+00	STAT6
Body Mass Index (BMI) (2010)	1.12	1	0	0.0	0.00	1.0e+00	SMAD3
Alcohol intake frequency.	1.12	2	0	0.0	0.00	1.0e+00	RPS26 STAT6
Chronotype (morning person)	1.11	2	0	0.0	0.00	1.0e+00	KIAA1109 MED24
Impedance of leg (right)	1.11	5	3	6.7	-0.23	7.1e-01	GPR182 RIN3 RP11-400F19.8 RPS26 ZNF652
Impedance of leg (left)	1.11	7	3	6.7	-0.44	3.2e-01	GPR182 RIN3 RP11-400F19.8 RPS26 S100A11 SLC22A5 ZNF652
Knee pain experienced in last month	1.10	1	0	0.0	0.00	1.0e+00	RP11-396B14.2
High cholesterol (Self-reported)	1.10	1	0	0.0	0.00	1.0e+00	FADS1
Qualifications: College or University degree	1.09	2	2	4.4	0.00	1.0e+00	AFF3 RPS26
Friendships satisfaction	1.09	1	0	0.0	0.00	1.0e+00	EFEMP2
Age started oral contraceptive pill	1.09	1	0	0.0	0.00	1.0e+00	RPS26
Neuroticism (Nagel 2018)	1.07	1	0	0.0	0.00	1.0e+00	PHF5A
Systolic blood pressure, automated reading	1.07	2	0	0.0	0.00	1.0e+00	DMWD STMN3
Reaction Time	1.06	1	0	0.0	0.00	1.0e+00	MED24
Weight	1.06	8	6	13.3	-0.45	1.9e-01	AC034220.3 IQCH P4HA2-AS1 RP11-400F19.8 RPS26 SLC22A5 SMAD3 TRIM38
Pulse rate	1.06	1	1	2.2	0.00	1.0e+00	FADS1
Body fat percentage	1.06	7	2	4.4	0.77	4.4e-02	IQCH PHF5A RERE RP11-400F19.8 SMAD3 TRIM38 ZNF76
Heel bone mineral density (BMD) T-score, automated (right)	1.05	2	2	4.4	0.00	1.0e+00	FADS1 RERE
Arm fat percentage (right)	1.05	5	3	6.7	0.67	2.1e-01	IQCH PHF5A RP11-400F19.8 SMAD3 ZNF76
Depressed Affect (Nagel 2018)	1.04	2	0	0.0	0.00	1.0e+00	PHF5A RERE
Waist circumference	1.04	4	3	6.7	0.38	6.2e-01	IQCH RP11-400F19.8 RPS26 SMAD3
Worry too long after embarrassment	1.04	2	0	0.0	0.00	1.0e+00	AHI1 IQCH
Schizophrenia (2014)	1.03	1	0	0.0	0.00	1.0e+00	STAT6
Mouth/teeth dental problems: Dentures	1.03	1	0	0.0	0.00	1.0e+00	TRIM38
Blood Red Count	1.02	12	6	13.3	0.13	6.6e-01	AFF3 AHI1 BACH2 FADS1 KIF11 KIF5A LINGO4 NDFIP1 POLI RPS26 SPPL3 TLR1
Systolic Blood Pressure	1.02	8	4	8.9	0.41	3.1e-01	CTD-2020K17.3 DMWD EEFSEC KIF11 RERE SIK2 SMAD3 ZNF652
Supplements: Vitamin C	1.02	1	0	0.0	0.00	1.0e+00	ORMDL3
Irritability	1.02	1	0	0.0	0.00	1.0e+00	FADS1
Trunk fat percentage	1.01	5	3	6.7	0.73	1.6e-01	IQCH PHF5A RP11-400F19.8 SMAD3 TRIM38
Arm fat percentage (left)	1.01	6	3	6.7	0.69	1.3e-01	IQCH PHF5A RP11-400F19.8 SMAD3 TRIM38 ZNF76
Neuroticism score	1.00	1	0	0.0	0.00	1.0e+00	PHF5A
Verbal and Numeric Reasoning (VNR)	0.99	2	0	0.0	0.00	1.0e+00	AFF3 RPS26
Qualifications: None of the above	0.99	1	1	2.2	0.00	1.0e+00	RPS26
Hair/balding pattern: Pattern 3	0.99	1	0	0.0	0.00	1.0e+00	AC034220.3
Neuroticism	0.97	4	0	0.0	-0.37	6.3e-01	AHI1 IQCH MED24 PHF5A
Leg fat mass (left)	0.97	7	3	6.7	0.52	2.4e-01	IQCH RERE RP11-400F19.8 RPS26 SMAD3 STMN3 TRIM38
Relative age of first facial hair	0.96	1	0	0.0	0.00	1.0e+00	SPPL3
Body mass index (BMI)	0.96	4	2	4.4	-0.93	6.7e-02	RP11-400F19.8 RPS26 SMAD3 TRIM38
Leg fat mass (right)	0.96	6	3	6.7	0.52	2.9e-01	IQCH RERE RP11-400F19.8 RPS26 SMAD3 TRIM38
Heel bone mineral density (BMD) T-score, automated (left)	0.95	2	0	0.0	0.00	1.0e+00	FADS1 RERE
Trunk fat mass	0.94	5	2	4.4	0.72	1.7e-01	IQCH PHF5A RP11-400F19.8 SMAD3 TRIM38
Whole body fat mass	0.93	7	3	6.7	0.53	2.2e-01	IQCH PHF5A RP11-400F19.8 RPS26 SMAD3 STMN3 TRIM38
Worry (Nagel 2018)	0.92	1	0	0.0	0.00	1.0e+00	TRIM38
BMI	0.92	8	4	8.9	0.28	4.9e-01	EEFSEC IQCH PTP4A1 RP11-400F19.8 RPS26 SMAD3 STMN3 TLR1
Arm fat mass (right)	0.92	5	4	8.9	0.35	5.6e-01	IQCH RP11-400F19.8 RPS26 SMAD3 TRIM38
Mean time to correctly identify matches	0.92	1	0	0.0	0.00	1.0e+00	MED24
Arm fat mass (left)	0.92	5	3	6.7	0.37	5.4e-01	IQCH RP11-400F19.8 RPS26 SMAD3 TRIM38
Overall health rating	0.91	1	1	2.2	0.00	1.0e+00	ZNF652
Heel T-Score	0.90	10	6	13.3	-0.16	6.6e-01	BACH2 FADS1 FPR3 IQCH KIF1B PHF5A RERE RIN3 RPS26 ZNF76
Hip circumference	0.83	4	1	2.2	1.00	4.6e-03	IQCH SMAD3 STMN3 TRIM38
Intelligence (Savage-Jansen 2018)	0.82	2	1	2.2	0.00	1.0e+00	AFF3 RPS26
Nervous feelings	0.81	1	0	0.0	0.00	1.0e+00	IQCH
Mood swings	0.79	1	0	0.0	0.00	1.0e+00	PHF5A
Qualifications: A levels/AS levels or equivalent	0.72	1	0	0.0	0.00	1.0e+00	RPS26
Hair Pigment	0.15	6	4	8.9	0.34	5.0e-01	AHI1 JAZF1 KIAA1432 KIF1B KIF5A ZNF76

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Whole Blood	13	0.652	2.3
GTEx	Breast Mammary Tissue (Male)	6	0.503	2.2
GTEx	Pancreas	8	0.490	2.2
GTEx	Spleen	10	0.709	2.2
NTR	Blood	15	0.624	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	17	0.678	2.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	9	0.542	2.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	9	0.534	2.2
GTEx	Artery Tibial	20	0.532	2.1
GTEx	Brain Cortex	9	0.870	2.1
GTEx	Brain Nucleus accumbens basal ganglia	7	0.809	2.1
GTEx	Brain Putamen basal ganglia	3	0.481	2.1
GTEx	Breast Mammary Tissue	10	0.507	2.1
GTEx	Cells Transformed fibroblasts	22	0.524	2.1
GTEx	Colon Transverse	11	0.533	2.1
GTEx	Heart Atrial Appendage	7	0.443	2.1
GTEx	Skin Sun Exposed Lower leg	18	0.495	2.1
GTEx	Thyroid	19	0.475	2.1
YFS	Blood	24	0.520	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	21	0.512	2.1
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.439	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	5	0.452	2.1
The Cancer Genome Atlas	Lung Adenocarcinoma	14	0.477	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	6	0.868	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	8	0.625	2.1
The Cancer Genome Atlas	Thyroid Carcinoma	28	0.543	2.1
GTEx	Adipose Visceral Omentum	8	0.393	2.0
GTEx	Artery Aorta	14	0.470	2.0
GTEx	Brain Cerebellar Hemisphere	5	0.336	2.0
GTEx	Brain Cerebellum	6	0.303	2.0
GTEx	Brain Frontal Cortex BA9	5	0.541	2.0
GTEx	Brain Hypothalamus	2	0.339	2.0
GTEx	Colon Sigmoid	5	0.342	2.0
GTEx	Esophagus Mucosa	15	0.452	2.0
GTEx	Esophagus Muscularis	13	0.402	2.0
GTEx	Lung	10	0.348	2.0
GTEx	Muscle Skeletal	14	0.484	2.0
GTEx	Nerve Tibial	15	0.347	2.0
GTEx	Ovary	5	0.551	2.0
GTEx	Pituitary	6	0.538	2.0
GTEx	Skin Not Sun Exposed Suprapubic	17	0.691	2.0
GTEx	Testis	16	0.507	2.0
METSIM	Adipose	19	0.412	2.0
ROSMAP	Brain Pre-frontal Cortex	20	0.455	2.0
CommonMind	Brain Pre-frontal Cortex	22	0.409	2.0
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	6	0.363	2.0
The Cancer Genome Atlas	Colon Adenocarcinoma	11	0.533	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	9	0.331	2.0
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.374	2.0
GTEx	Adipose Subcutaneous	9	0.258	1.9
GTEx	Breast Mammary Tissue (Female)	6	0.365	1.9
GTEx	Cells EBV-transformed lymphocytes	6	0.422	1.9
GTEx	Esophagus Gastroesophageal Junction	5	0.346	1.9
GTEx	Liver	3	0.418	1.9
GTEx	Prostate	4	0.479	1.9
GTEx	Stomach	5	0.344	1.9
The Cancer Genome Atlas	Breast Invasive Carcinoma	21	0.477	1.9
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	7	0.685	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	17	0.395	1.9
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	15	0.324	1.9
GTEx	Adrenal Gland	5	0.343	1.8
GTEx	Brain Caudate basal ganglia	3	0.326	1.8
GTEx	Heart Left Ventricle	5	0.327	1.8
GTEx	Uterus	1	0.176	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.456	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.377	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.187	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.8
GTEx	Artery Coronary	1	0.085	1.7
GTEx	Brain Hippocampus	2	0.382	1.7
GTEx	Small Intestine Terminal Ileum	1	0.217	1.7
GTEx	Vagina	0	0.000	1.7